NVCR - Novocure Ltd Stock Price, Fair Value and News

12.73USD-0.84 (-6.19%)Market Closed

Market Summary

USD12.73-0.84

Market Closed

-6.19%

NVCR Stock Price

View Fullscreen

NVCR RSI Chart

NVCR Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-6.58

Price/Sales (Trailing)

2.68

EV/EBITDA

-9.36

Price/Free Cashflow

-13.57

NVCR Price/Sales (Trailing)

NVCR Profitability

Operating Margin

74.81%

EBT Margin

-37.64%

Return on Equity

-57.12%

Return on Assets

-18.06%

Free Cashflow Yield

-7.37%

NVCR Fundamentals

NVCR Revenue

Revenue (TTM)

509.3M

Rev. Growth (Yr)

4.17%

Rev. Growth (Qtr)

5.08%

NVCR Earnings

Earnings (TTM)

-207.0M

Earnings Growth (Yr)

-26.21%

Earnings Growth (Qtr)

4.86%

Breaking Down NVCR Revenue

Last 7 days

-10.2%

Last 30 days

-8.9%

Last 90 days

1.1%

Trailing 12 Months

-79.7%

How does NVCR drawdown profile look like?

NVCR Financial Health

Current Ratio

5.78

Debt/Equity

1.57

Debt/Cashflow

-0.13

NVCR Investor Care

Shares Dilution (1Y)

1.55%

Diluted EPS (TTM)

-1.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	522.5M	507.7M	504.0M	509.3M
2022	537.9M	545.2M	542.6M	537.8M
2021	527.2M	544.8M	545.8M	535.0M
2020	379.8M	409.0M	449.6M	494.4M
2019	269.3M	294.5M	321.8M	351.3M
2018	194.3M	217.4M	232.1M	248.1M
2017	104.7M	125.2M	153.6M	177.0M
2016	40.9M	52.3M	65.0M	82.9M
2015	19.9M	24.3M	28.7M	33.1M
2014	0	0	12.9M	15.5M
2013	0	0	0	10.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Novocure Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	leonard frank x	sold	-13,448	16.01	-840	evp, pres., novocure oncology
Mar 04, 2024	groenhuysen wilhelmus cm	sold	-19,484	16.01	-1,217	chief operating officer
Mar 01, 2024	leonard frank x	sold	-26,909	16.0269	-1,679	evp, pres., novocure oncology
Mar 01, 2024	groenhuysen wilhelmus cm	sold	-33,768	16.0269	-2,107	chief operating officer
Feb 28, 2024	leonard frank x	sold	-33,544	16.1428	-2,078	evp, pres., novocure oncology
Feb 28, 2024	groenhuysen wilhelmus cm	sold	-37,176	16.1428	-2,303	chief operating officer
Feb 27, 2024	puri michal nath	acquired	1,166,660	16.3	71,574	chief human resources officer
Feb 27, 2024	leupin nicolas	acquired	833,321	16.3	51,124	chief medical officer
Feb 27, 2024	leonard frank x	acquired	1,666,660	16.3	102,249	evp, pres., novocure oncology
Feb 27, 2024	cordova ashley	acquired	1,666,660	16.3	102,249	chief financial officer

Which funds bought or sold NVCR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	AdvisorNet Financial, Inc	added	83.33	41,175	85,965	0.01%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	unchanged	-	3.00	63.00	-%
Apr 11, 2024	Roble, Belko & Company, Inc	unchanged	-	-	-	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	new	-	328	328	-%
Apr 09, 2024	ADIRONDACK TRUST CO	unchanged	-	32.00	1,563	-%
Apr 09, 2024	Rise Advisors, LLC	unchanged	-	21.00	469	-%
Apr 08, 2024	TOMPKINS FINANCIAL CORP	unchanged	-	70.00	1,563	-%
Apr 05, 2024	GAMMA Investing LLC	added	277	34,407	45,014	0.01%
Apr 05, 2024	CWM, LLC	added	6.61	3,000	29,000	-%
Apr 05, 2024	NBC SECURITIES, INC.	new	-	1,000	1,000	-%

Are Funds Buying or Selling NVCR?

Are funds buying NVCR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NVCR

No. of Funds

Unveiling Novocure Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.13%	9,759,087	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital international investors	8.3%	8,896,076	SC 13G/A
Feb 09, 2024	capital world investors	3.1%	3,276,996	SC 13G/A
Feb 09, 2024	blackrock inc.	8.2%	8,792,035	SC 13G/A
Dec 11, 2023	capital world investors	5.5%	5,834,080	SC 13G/A
Nov 09, 2023	baillie gifford & co	4.77%	5,095,777	SC 13G/A
Feb 13, 2023	capital world investors	12.3%	12,899,395	SC 13G/A
Feb 13, 2023	capital international investors	7.8%	8,155,909	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Novocure Ltd

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	PRE 14A	PRE 14A
Mar 27, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Mar 04, 2024	144	Notice of Insider Sale Intent
Mar 04, 2024	144	Notice of Insider Sale Intent
Mar 01, 2024	144	Notice of Insider Sale Intent
Mar 01, 2024	144	Notice of Insider Sale Intent
Mar 01, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Novocure Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	188.9B	40.1B	-5.73%	4.72%	33.01	4.71	-8.12%	-17.45%
BDX	67.8B	19.5B	-0.88%	-8.17%	53.97	3.48	4.02%	-22.04%
ALGN	22.9B	3.9B	-3.10%	-11.00%	51.41	5.92	3.42%	23.09%
BAX	20.3B	14.8B	-3.77%	-6.99%	7.66	1.37	2.12%	209.17%
MID-CAP
ATR	9.1B	3.5B	-1.99%	15.94%	32.07	2.62	4.97%	18.89%
HSIC	9.1B	12.3B	-5.16%	-14.19%	21.85	0.74	-2.44%	-22.68%
BIO	8.8B	2.7B	-9.88%	-37.29%	-13.77	3.29	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.94%	-24.93%	-47.62	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-0.71%	17.46%	-565.84	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-6.94%	-4.63%	11.73	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-3.79%	-17.24%	-1.94	0.41	7.73%	-1066.14%
ANIK	376.4M	166.7M	-0.35%	-8.55%	-4.55	2.26	6.67%	-456.34%
ANGO	253.5M	324.0M	17.88%	-30.36%	-1.32	0.78	-3.19%	-337.41%
APYX	47.8M	52.3M	-22.91%	-54.00%	-2.55	0.91	17.61%	19.28%
AEMD	3.8M	3.7M	-16.18%	262.50%	-0.31	1.01	5.77%	8.23%

Novocure Ltd News

Latest updates

Novocure Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	5.1%	134	127	126	122	128	131	141	138	133	134	134	135	144	133	116	102	99.00	92.00	87.00	73.00	70.00
Cost Of Revenue	1.4%	33.00	32.00	34.00	30.00	29.00	30.00	29.00	28.00	30.00	30.00	29.00	26.00	28.00	28.00	25.00	24.00	25.00	23.00	21.00	20.00	23.00
Gross Profit	6.3%	101	95.00	92.00	93.00	100	101	112	110	104	103	105	108	116	104	90.00	77.00	74.00	69.00	66.00	53.00	47.00
Operating Expenses	-0.3%	153	153	155	153	143	126	133	111	127	112	117	108	104	89.00	84.00	81.00	74.00	65.00	64.00	60.00	55.00
S&GA Expenses	2.1%	59.00	58.00	58.00	51.00	50.00	41.00	45.00	38.00	39.00	33.00	34.00	31.00	31.00	29.00	28.00	29.00	27.00	24.00	24.00	22.00	21.00
R&D Expenses	1.3%	54.00	54.00	55.00	60.00	55.00	52.00	57.00	42.00	57.00	48.00	50.00	46.00	44.00	33.00	30.00	25.00	24.00	19.00	19.00	17.00	15.00
EBITDA Margin	-24.1%	-0.35*	-0.29*	-0.24*	-0.19*	-0.12*	-0.12*	-0.10*	-0.08*	-0.08*	-0.01*	0.03*	0.07*	-	-	-	-	-	-	-	-	-
Interest Expenses	-378.8%	-27.94	10.00	9.00	9.00	3.00	1.00	-2.23	-1.71	0.00	0.00	0.00	0.00	0.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Income Taxes	576.6%	9.00	1.00	4.00	2.00	5.00	3.00	1.00	2.00	1.00	3.00	1.00	1.00	4.00	2.00	2.00	-9.76	-5.85	-0.63	1.00	4.00	5.00
Earnings Before Taxes	20.1%	-38.53	-48.22	-53.90	-51.08	-32.56	-23.42	-23.36	-2.51	-25.57	-10.53	-13.23	-2.73	9.00	11.00	4.00	-5.81	-1.59	1.00	-0.04	-8.49	-10.82
EBT Margin	-2.1%	-0.38*	-0.37*	-0.32*	-0.25*	-0.15*	-0.14*	-0.11*	-0.10*	-0.10*	-0.03*	0.01*	0.04*	-	-	-	-	-	-	-	-	-
Net Income	4.9%	-47.08	-49.48	-57.42	-53.06	-37.30	-26.58	-24.01	-4.65	-26.46	-13.12	-14.64	-4.13	5.00	9.00	2.00	4.00	4.00	2.00	-1.27	-12.15	-15.63
Net Income Margin	-3.9%	-0.41*	-0.39*	-0.34*	-0.27*	-0.17*	-0.15*	-0.13*	-0.11*	-0.11*	-0.05*	-0.01*	0.02*	-	-	-	-	-	-	-	-	-
Free Cashflow	19.5%	-21.38	-26.57	-29.67	-22.81	-10.14	17.00	12.00	-8.78	0.00	21.00	24.00	14.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.0%	1,146	1,146	1,159	1,174	1,192	1,174	1,163	1,150	1,139	1,120	1,097	1,068	1,052	431	529	502	479	444	406	370	340
Current Assets	-1.3%	1,034	1,048	1,065	1,089	1,112	1,102	1,095	1,081	1,074	1,069	1,046	1,015	999	383	488	462	440	407	370	336	321
Cash Equivalents	55.5%	241	155	157	187	115	244	368	192	209	691	361	326	246	235	198	183	179	210	182	154	143
Inventory	3.7%	38.00	37.00	33.00	32.00	29.00	27.00	30.00	29.00	24.00	23.00	27.00	28.00	27.00	26.00	26.00	23.00	24.00	24.00	25.00	24.00	23.00
Net PPE	13.0%	51.00	46.00	41.00	36.00	33.00	30.00	27.00	25.00	23.00	12.00	12.00	12.00	11.00	10.00	11.00	10.00	9.00	8.00	8.00	8.00	8.00
Liabilities	4.1%	784	753	743	742	750	729	721	714	729	707	700	695	575	124	261	261	262	253	247	244	228
Current Liabilities	14.0%	179	157	150	149	159	141	135	128	143	125	116	110	114	95.00	85.00	84.00	86.00	80.00	74.00	71.00	65.00
Long Term Debt	0.1%	569	568	567	566	566	565	564	563	562	561	561	560	430	-	150	149	149	149	149	149	149
LT Debt, Non Current	0.1%	569	568	567	566	566	565	564	563	562	561	561	560	430	-	150	149	149	149	149	149	149
Shareholder's Equity	-7.9%	362	394	416	432	441	445	442	436	410	413	397	372	477	307	268	242	218	190	159	126	112
Retained Earnings	-5.0%	-985	-938	-888	-831	-778	-741	-714	-690	-685	-659	-646	-631	-631	-635	-645	-646	-650	-655	-657	-655	-643
Additional Paid-In Capital	1.5%	1,353	1,334	1,307	1,266	1,222	1,189	1,158	1,128	1,100	1,074	1,045	1,006	1,111	946	917	893	871	848	818	784	757
Shares Outstanding	0.3%	107	107	107	106	105	105	105	104	103	104	103	103	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,415	-	-	-	2,831	-	-	-	9,486	-	-	-	2,774	-	-	-	3,943	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	24.6%	-14.56	-19.31	-22.74	-16.73	-3.71	22.00	16.00	-3.69	14.00	24.00	26.00	18.00	53.00	31.00	13.00	2.00	7.00	15.00	9.00	-4.32	17.00
Share Based Compensation	-33.8%	17.00	26.00	33.00	39.00	30.00	26.00	26.00	25.00	22.00	26.00	28.00	19.00	20.00	20.00	19.00	17.00	15.00	14.00	14.00	10.00	11.00
Cashflow From Investing	470.7%	99.00	17.00	-13.90	82.00	-128	-150	156	-17.41	-499	303	-2.62	54.00	-613	147	-3.31	-3.11	-46.76	-2.17	-1.75	-0.99	-1.79
Cashflow From Financing	63.1%	2.00	1.00	8.00	5.00	3.00	4.00	5.00	3.00	4.00	3.00	11.00	8.00	571	-140	5.00	5.00	9.00	15.00	21.00	17.00	3.00

NVCR Income Statement

2023-12-31

Consolidated statements of operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenues	$ 509,338	$ 537,840	$ 535,031
Cost of revenues	128,280	114,867	114,877
Gross profit	381,058	422,973	420,154
Operating costs and expenses:
Research, development and clinical studies	223,062	206,085	201,303
Sales and marketing	226,809	173,658	137,057
General and administrative	164,057	132,753	126,127
Total operating costs and expenses	613,928	512,496	464,487
Operating income (loss)	(232,870)	(89,523)	(44,333)
Financial (expenses) income, net	41,130	7,677	(7,742)
Total income (loss) before income taxes	(191,740)	(81,846)	(52,075)
Income tax	15,303	10,688	6,276
Net income (loss)	$ (207,043)	$ (92,534)	$ (58,351)
Basic net income (loss) per ordinary share (in usd per share)	$ (1.95)	$ (0.88)	$ (0.56)
Diluted net income (loss) per ordinary share (in usd per share)	$ (1.95)	$ (0.88)	$ (0.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	106,391,178	104,660,476	103,433,274
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	106,391,178	104,660,476	103,433,274

NVCR Balance Sheet

2023-12-31

Consolidated balance sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 240,821	$ 115,326
Short-term investments	669,795	854,099
Restricted cash	1,743	508
Trade receivables, net	61,221	86,261
Receivables and prepaid expenses	22,677	25,959
Inventories	38,152	29,376
Total current assets	1,034,409	1,111,529
Long-term assets:
Property and equipment, net	51,479	32,678
Field equipment, net	11,384	12,684
Right-of-use assets	34,835	23,596
Other long-term assets	14,022	11,161
Total long-term assets	111,720	80,119
Total assets	1,146,129	1,191,648
Current liabilities:
Trade payables	94,391	85,197
Other payables, lease liabilities and accrued expenses	84,724	73,580
Total current liabilities	179,115	158,777
Long-term liabilities:
Long-term debt, net	568,822	565,509
Deferred revenues	0	2,878
Long term leases	27,420	18,762
Employee benefit liabilities	8,258	4,404
Other long-term liabilities	18	148
Total long-term liabilities	604,518	591,701
Total liabilities	783,633	750,478
Commitments and contingencies
Shareholders’ equity:
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 107,075,754 shares and 105,049,411 shares at December 31, 2023 and December 31, 2022 respectively;	0	0
Additional paid-in capital	1,353,468	1,222,063
Accumulated other comprehensive income (loss)	(5,469)	(2,433)
Retained earnings (accumulated deficit)	(985,503)	(778,460)
Total shareholders’ equity	362,496	441,170
Total liabilities and shareholders’ equity	$ 1,146,129	$ 1,191,648

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

CEO	Mr. Asaf Danziger
WEBSITE	novocure.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1320

Novocure Ltd Frequently Asked Questions

What is the ticker symbol for Novocure Ltd? What does NVCR stand for in stocks?

NVCR is the stock ticker symbol of Novocure Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Novocure Ltd (NVCR)?

As of Mon Apr 15 2024, market cap of Novocure Ltd is 1.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVCR stock?

You can check NVCR's fair value in chart for subscribers.

What is the fair value of NVCR stock?

You can check NVCR's fair value in chart for subscribers. The fair value of Novocure Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Novocure Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVCR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Novocure Ltd a good stock to buy?

The fair value guage provides a quick view whether NVCR is over valued or under valued. Whether Novocure Ltd is cheap or expensive depends on the assumptions which impact Novocure Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVCR.

What is Novocure Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, NVCR's PE ratio (Price to Earnings) is -6.58 and Price to Sales (PS) ratio is 2.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVCR PE ratio will change depending on the future growth rate expectations of investors.